Spillantini MG, Crowther RA, Jakes R et al (1998) alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with lewy bodies. Proc Natl Acad Sci USA 95:6469–6473. https://doi.org/10.1073/pnas.95.11.6469

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pajares M, Rojo IA, Manda G et al (2020) Inflammation in Parkinson’s disease: mechanisms and therapeutic implications. Cells 9. https://doi.org/10.3390/cells9071687

Bloem BR, Okun MS, Klein C (2021) Parkinson’s disease. Lancet (London, England) 397:2284–2303. https://doi.org/10.1016/S0140-6736(21)00218-X

Article  CAS  PubMed  Google Scholar 

Harms AS, Yang Y-T, Tansey MG (2023) Central and peripheral innate and adaptive immunity in Parkinson’s disease. Sci Transl Med 15:eadk3225. https://doi.org/10.1126/scitranslmed.adk3225

Article  CAS  PubMed  Google Scholar 

Emre M, Aarsland D, Brown R et al (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 22:1689–707; quiz 1837. https://doi.org/10.1002/mds.21507

Article  PubMed  Google Scholar 

Wallace ER, Segerstrom SC, van Horne CG et al (2022) Meta-Analysis of Cognition in Parkinson’s Disease Mild Cognitive Impairment and Dementia Progression. Neuropsychol Rev 32:149–160. https://doi.org/10.1007/s11065-021-09502-7

Article  PubMed  Google Scholar 

Hely MA, Reid WGJ, Adena MA et al (2008) The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Movement disorders : official journal of the Movement Disorder Society 23:837–844. https://doi.org/10.1002/mds.21956

Article  PubMed  Google Scholar 

Schapira AHV, Chaudhuri KR, Jenner P (2017) Non-motor features of Parkinson disease. Nat Rev Neurosci 18:435–450. https://doi.org/10.1038/nrn.2017.62

Article  CAS  PubMed  Google Scholar 

Reijnders JSAM, Ehrt U, Weber WEJ et al (2008) A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord 23:183–9; quiz 313. https://doi.org/10.1002/mds.21803

Article  PubMed  Google Scholar 

Li L, Wang Z, You Z, Huang J (2023) Prevalence and Influencing Factors of Depression in Patients with Parkinson’s Disease. Alpha psychiatry 24:234–238. https://doi.org/10.5152/alphapsychiatry.2023.231253

Article  PubMed  PubMed Central  Google Scholar 

Tan E-K, Chao Y-X, West A et al (2020) Parkinson disease and the immune system - associations, mechanisms and therapeutics. Nat Rev Neurol 16:303–318. https://doi.org/10.1038/s41582-020-0344-4

Article  PubMed  Google Scholar 

Sulzer D, Alcalay RN, Garretti F et al (2017) T cells from patients with Parkinson’s disease recognize α-synuclein peptides. Nature 546:656–661. https://doi.org/10.1038/nature22815

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu T-W, Chen C-M, Chang K-H (2022) Biomarker of neuroinflammation in Parkinson’s disease. Int J Mol Sci 23. https://doi.org/10.3390/ijms23084148

Reale M, Iarlori C, Thomas A et al (2009) Peripheral cytokines profile in Parkinson’s disease. Brain Behav Immun 23:55–63. https://doi.org/10.1016/j.bbi.2008.07.003

Article  CAS  PubMed  Google Scholar 

Pessoa Rocha N, Reis HJ, Vanden Berghe P, Cirillo C (2014) Depression and cognitive impairment in Parkinson’s disease: a role for inflammation and immunomodulation? NeuroImmunoModulation 21:88–94. https://doi.org/10.1159/000356531

Article  CAS  PubMed  Google Scholar 

Shaw BC, Anders VR, Tinkey RA et al (2023) Immunity impacts cognitive deficits across neurological disorders. J Neurochem. https://doi.org/10.1111/jnc.15999

Article  PubMed  Google Scholar 

Paul KC, Kusters C, Furlong M et al (2022) Immune system disruptions implicated in whole blood epigenome-wide association study of depression among Parkinson’s disease patients. Brain, behavior, & immunity - health 26:100530. https://doi.org/10.1016/j.bbih.2022.100530

Article  CAS  Google Scholar 

Brosseron F, Kolbe C-C, Santarelli F et al (2020) Multicenter Alzheimer’s and Parkinson’s disease immune biomarker verification study. Alzheimer’s & dementia : the journal of the Alzheimer’s Association 16:292–304. https://doi.org/10.1016/j.jalz.2019.07.018

Article  Google Scholar 

Assarsson E, Lundberg M, Holmquist G et al (2014) Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS ONE 9:e95192. https://doi.org/10.1371/journal.pone.0095192

Article  CAS  PubMed  PubMed Central  Google Scholar 

Postuma RB, Berg D, Stern M et al (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Movement disorders : official journal of the Movement Disorder Society 30:1591–1601. https://doi.org/10.1002/mds.26424

Article  PubMed  Google Scholar 

Goetz CG, Tilley BC, Shaftman SR et al (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Movement disorders : official journal of the Movement Disorder Society 23:2129–2170. https://doi.org/10.1002/mds.22340

Article  PubMed  Google Scholar 

Hoops S, Nazem S, Siderowf AD et al (2009) Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 73:1738–1745. https://doi.org/10.1212/WNL.0b013e3181c34b47

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dalrymple-Alford JC, MacAskill MR, Nakas CT et al (2010) The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology 75:1717–1725. https://doi.org/10.1212/WNL.0b013e3181fc29c9

Article  CAS  PubMed  Google Scholar 

Litvan I, Goldman JG, Tröster AI et al (2012) Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Movement disorders : official journal of the Movement Disorder Society 27:349–356. https://doi.org/10.1002/mds.24893

Article  PubMed  Google Scholar 

Tomlinson CL, Stowe R, Patel S et al (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Movement disorders : official journal of the Movement Disorder Society 25:2649–2653. https://doi.org/10.1002/mds.23429

Article  PubMed  Google Scholar 

Jabbari E, Woodside J, Guo T et al (2019) Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry 90:768–773. https://doi.org/10.1136/jnnp-2018-320151

Article  PubMed  Google Scholar 

Paslawski W, Khosousi S, Hertz E et al (2023) Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson’s disease. Translational neurodegeneration 12:42. https://doi.org/10.1186/s40035-023-00374-w

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maple-Grødem J, Ushakova A, Pedersen KF et al (2023) Identification of diagnostic and prognostic biomarkers of PD using a multiplex proteomics approach. Neurobiol Dis 186:106281. https://doi.org/10.1016/j.nbd.2023.106281

Article  CAS  PubMed  Google Scholar 

Santaella A, Kuiperij HB, van Rumund A et al (2020) Inflammation biomarker discovery in Parkinson’s disease and atypical parkinsonisms. BMC Neurol 20:26. https://doi.org/10.1186/s12883-020-1608-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bartl M, Dakna M, Schade S et al (2023) Blood Markers of Inflammation, Neurodegeneration, and Cardiovascular Risk in Early Parkinson’s Disease. Movement disorders : official journal of the Movement Disorder Society 38:68–81. https://doi.org/10.1002/mds.29257

Article  CAS  PubMed  Google Scholar 

Arndt B, Krieger T, Kalinski T et al (2011) The transmembrane adaptor protein SIT inhibits TCR-mediated signaling. PLoS ONE 6:e23761. https://doi.org/10.1371/journal.pone.0023761